DTC And FDA: “Brief Summary” Improvements Are Priority For McClellan
Executive Summary
FDA will address physicians' "legitimate" concern that direct-to-consumer ads do not provide balanced risk-benefit information, Commissioner McClellan told the National Association of Health Underwriters legislative conference March 25 in Washington, D.C
You may also be interested in...
Pfizer DTC Comments Prescribe Limited Risk Info, Reliance On Physicians
Risk information in direct-to-consumer ads should be designed to prompt more patient-physician dialogue, Pfizer suggested in comments to FDA
Pfizer DTC Comments Prescribe Limited Risk Info, Reliance On Physicians
Risk information in direct-to-consumer ads should be designed to prompt more patient-physician dialogue, Pfizer suggested in comments to FDA
DTC Future: Firms Could Pool Dollars For Educational Spots; “Got Drugs?”
Pharmaceutical companies should devote more of their advertising budgets to collective disease education efforts, Rx Insight CEO Bob Ehrlich said